Article citationsMore>>

Meng, Z., et al. (2021) The SGLT2 Inhibitor Empagliflozin Negatively Regulates IL-17/IL-23 Axis-Mediated Inflammatory Responses in T2DM with NAFLD via the AMPK/mTOR/Autophagy Pathway. International Immunopharmacology, 94, Article ID: 107492.
https://doi.org/10.1016/j.intimp.2021.107492

has been cited by the following article:

• TITLE: Progress in the Study of the Hepatoprotective Effect of SGLT2i on NAFLD Patients with T2DM

  AUTHORS: Fan Yang, Xiaoping Tan

  KEYWORDS: Sodium-Glucose Cotransporter-2 Inhibitors, Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.12 No.1, January 19, 2024

  ABSTRACT: In recent years, the progress of NAFLD has become an important health problem, and the prevention or delay of progress in NAFLD is a major key point. Whether or not to combine T2MD, people are interested in the mechanisms and efficacy of SGLT2i for NAFLD. In this review, we summarized the current clinical research on SGLT2i for the combination of T2MD’s NAFLD patients, and the latest evidence of external or animal experiments. These evidences will help us to more accurately understand the protective effects of SGLT2i in NAFLD. Lifestyle changes are still essential to prevent and treat NAFLD, and for all kinds of drugs that treat NAFLD in clinical trials, SGLT2i may be one of the promising treatments.